Repatha Dosing Schedules: Every 2 Weeks vs. Monthly

Repatha (evolocumab) comes in two standard dose options for adults: 140 mg injected under the skin every two weeks, or 420 mg once a month. Both schedules lower LDL cholesterol by roughly the same amount, and the choice between them usually comes down to personal preference and convenience. The dosing picture gets more specific for certain conditions, age groups, and organ-function situations, and there are practical details about storage, switching schedules, and real-world adherence that matter once you’re actually using the drug.

How the Two Adult Schedules Work

For the most common uses of Repatha, including primary hyperlipidemia, established atherosclerotic cardiovascular disease, and heterozygous familial hypercholesterolemia (HeFH), the recommended dose is either 140 mg every two weeks or 420 mg once monthly.¹ The 140 mg dose is given as a single injection using a prefilled syringe or autoinjector. The 420 mg monthly dose requires three separate 140 mg injections given back to back, all completed within 30 minutes.² An alternative delivery method for the 420 mg dose is the Pushtronex on-body infusor, which delivers the full dose over about five minutes through a single wearable device. Injection sites include the thigh, abdomen, or upper arm.

The LDL-lowering effect of the two schedules is comparable. In clinical trials, both the every-two-week and monthly regimens reduced LDL cholesterol by similar percentages when added to statin therapy.³ That means your doctor is unlikely to push you toward one schedule over the other based on effectiveness alone. Some people prefer the monthly schedule because it means fewer injections overall, while others prefer every two weeks because each individual session involves just one shot.

Dosing for Homozygous Familial Hypercholesterolemia

Homozygous familial hypercholesterolemia (HoFH) is a rarer, more severe form of inherited high cholesterol. For these patients, the recommended starting dose is 420 mg once monthly, given as three consecutive injections within 30 minutes. If the cholesterol response isn’t adequate after 12 weeks, the dose can be increased to 420 mg every two weeks.⁴ That higher-frequency option reflects the reality that people with HoFH often have very limited LDL receptor activity, so the drug faces a tougher biological challenge.

One practical detail worth knowing: if you’re switching between dosing schedules, the first dose of the new regimen should be given on the date the next dose of the old regimen would have been due.⁵ You don’t need a washout period or overlap. You just pick up where the old schedule left off.

Pediatric Use

Repatha’s FDA approval now extends down to age 10 for patients with heterozygous familial hypercholesterolemia.⁶ In a randomized trial of patients aged 10 to 17 with HeFH, the dose used was 420 mg monthly by subcutaneous injection, the same monthly dose used in adults. Children in the trial had to be on stable lipid-lowering therapy for at least four weeks before starting, and they needed an LDL cholesterol level at or above 130 mg/dL. Side-effect rates were similar between the evolocumab and placebo groups in that study.⁷

For younger children with HoFH, the picture is less established. The label’s pediatric HoFH indication covers patients aged 10 and older, using the same 420 mg monthly schedule that adults receive. Whether Repatha is useful or safe in children under 10 remains an open question, as clinical trial data in that age range are lacking.

Why Repatha Works the Way It Does

Repatha is a monoclonal antibody that targets a protein called PCSK9. Under normal circumstances, PCSK9 tags LDL receptors on liver cells for destruction. Fewer LDL receptors on the liver means less LDL cholesterol gets pulled out of the bloodstream, so cholesterol levels climb. By binding to PCSK9, evolocumab prevents that receptor-destroying process, allowing the liver to clear more LDL from the blood.⁸

This mechanism explains several dosing realities. The drug has a half-life of roughly 11 to 17 days, which is why the every-two-week schedule works. By the time the next dose is due, circulating drug levels have dropped enough that PCSK9 is starting to reassert itself. The monthly schedule uses a larger dose to sustain suppression over a longer interval. In pharmacokinetic studies, unbound PCSK9 levels drop by more than 80% within hours of a single dose, and LDL reductions become apparent within a few days.⁹

Kidney and Liver Impairment

One of the cleaner aspects of Repatha’s dosing profile is that you don’t need dose adjustments for kidney or liver problems in many situations. Because evolocumab is a large protein broken down by the body’s normal protein-recycling pathways rather than filtered through the kidneys, renal impairment doesn’t significantly alter its behavior. A dedicated study in patients with severe kidney impairment and those on hemodialysis found no meaningful differences in safety or drug performance compared to people with normal kidney function. No one in the study developed antibodies against evolocumab, and no adverse events were judged to be drug-related.¹⁰

For liver impairment, the story is similar but with a caveat. In people with mild or moderate liver dysfunction, evolocumab lowered PCSK9 and LDL cholesterol effectively, and no dose adjustment is recommended.¹¹ Although blood levels of the unbound drug were lower in people with moderate liver impairment, the drug still achieved strong PCSK9 suppression and LDL reduction, suggesting the lower exposure doesn’t translate into reduced effectiveness.¹² However, there are no data on severe liver impairment, so that remains uncharted territory.¹³

Combining Repatha with Statins and Ezetimibe

Repatha is almost always used alongside other cholesterol-lowering drugs rather than on its own. The most common pairing is with a statin, and sometimes ezetimibe is added as a third agent. In the LAPLACE-2 trial, which tested evolocumab on top of moderate- or high-intensity statin therapy, the drug reduced LDL cholesterol by roughly 63% to 75% beyond what the statin was already achieving.¹⁴ These numbers are roughly comparable between the every-two-week and monthly dosing arms.

Adding ezetimibe to the statin-plus-Repatha combination can push LDL levels even lower. All three drugs attack cholesterol through different pathways: statins reduce cholesterol production in the liver, ezetimibe blocks cholesterol absorption in the gut, and evolocumab boosts LDL receptor recycling. Because they complement each other, the combined effect is additive or even synergistic.¹⁵ From a dosing standpoint, Repatha doesn’t need any adjustment when used alongside statins or ezetimibe.

When LDL Goes Very Low

Because Repatha is so effective, especially in combination therapy, some patients end up with LDL levels well below what was considered normal a generation ago. Levels under 25 mg/dL are not uncommon in clinical trials. This sometimes prompts an understandable concern: is there a floor below which LDL becomes dangerously low?

The current evidence suggests that very low LDL levels are generally safe and may even be beneficial for people at high cardiovascular risk. A bigger practical problem is the opposite scenario: clinicians or patients getting nervous about low LDL numbers and scaling back treatment, which can leave patients exposed to unnecessarily high cardiovascular risk.¹⁶ If your LDL drops to a very low level on Repatha and your doctor wants to back off the dose, it’s worth having a conversation about whether the perceived risk of low LDL is based on evidence or on instinct. In most cases, maintaining the lower level is the safer bet for cardiovascular prevention.

Choosing Between Every Two Weeks and Once Monthly

Real-world data suggest that most people stick with whichever schedule they start on. In a study of more than 2,300 patients, about three-quarters of those initially assigned to monthly dosing chose to stay monthly, and about 70% of those who started on every-two-week dosing stayed on that schedule. Only about 5% to 8% of patients switched regimens again after making an initial choice, and adherence rates were comparable regardless of schedule.¹⁷ Dropout rates were also similar: about 2% in each group stopped after the first dose and didn’t continue.

There are a few practical factors worth considering. The every-two-week schedule involves one injection per session and a smaller volume, which can mean less discomfort and quicker administration. The monthly schedule means only 12 injection days per year instead of 26, but each session involves three shots or the use of the on-body infusor. If you travel frequently and need to bring the drug along, fewer sessions might be more convenient. If you dislike needles and prefer to get each encounter over with quickly, the single-injection biweekly option might feel more manageable.

Storing Repatha Properly

Repatha is a biologic, which means it’s sensitive to temperature. The prefilled syringes and autoinjectors should be kept refrigerated at 2°C to 8°C (about 36°F to 46°F). Once removed from the refrigerator, the drug can be kept at room temperature (up to 25°C or 77°F) for up to 30 days in the original carton, but it should not be returned to the refrigerator after warming. It should also never be frozen or shaken.

An experimental study looked at what happens when PCSK9 inhibitors, including evolocumab, are left at room temperature without a cold pack. After 9 and 18 hours at room temperature, the drug’s ability to inhibit PCSK9 dropped meaningfully. But when stored in a cooler with a cold pack, the drug maintained its activity through 9 and 18 hours with no statistically significant decline.¹⁸ This matters most during travel or periods without reliable refrigeration. A simple insulated bag with a cold pack can preserve the drug’s effectiveness for at least several hours.

How Repatha’s Dosing Compares to Other PCSK9-Targeting Drugs

The other injectable PCSK9 inhibitor on the market, alirocumab (Praluent), has a similar dosing structure: it’s also given every two weeks or monthly by subcutaneous injection. The dosing intervals and general logistics are comparable, so switching between the two isn’t a major adjustment from a scheduling standpoint, though the specific milligram doses differ.

A newer option in the PCSK9 space is inclisiran (Leqvio), which works through a different mechanism. Instead of blocking PCSK9 protein in the bloodstream the way evolocumab does, inclisiran prevents PCSK9 from being made in the first place by silencing the gene’s messenger RNA inside liver cells. The practical upshot is a dramatically different dosing schedule: after two initial doses three months apart, inclisiran is given just twice a year. That biannual schedule is a significant convenience advantage and may improve long-term adherence.¹⁹ However, inclisiran must be administered by a healthcare professional in a clinical setting, whereas Repatha is designed for self-injection at home. So the trade-off is fewer injections per year with inclisiran versus more flexibility and independence with evolocumab.

Cost and Access Realities

Repatha’s list price has been a significant barrier since its launch, though the manufacturer reduced it substantially in 2018 and again later. Cost-effectiveness analyses have found that the drug’s value depends heavily on how high a patient’s cardiovascular risk actually is. In one updated analysis of patients with very high-risk atherosclerotic cardiovascular disease, the incremental cost-effectiveness ratio ranged widely depending on baseline event rates, from less than $8,000 per quality-adjusted life year at the highest risk levels to roughly $57,000 at lower risk levels within that population.²⁰ For context, treatments under about $50,000 to $100,000 per QALY are generally considered cost-effective by U.S. standards. The drug looks like a better deal for people who are likeliest to have a heart attack or stroke without it, and a harder sell for people at moderate risk.

Insurance coverage varies. Many plans require prior authorization and documentation that statins alone aren’t controlling LDL adequately, or that the patient can’t tolerate statins at effective doses. If you’re prescribed Repatha, expect some paperwork. Manufacturer copay assistance programs exist for commercially insured patients, and patient assistance programs cover some uninsured individuals, but navigating the system takes effort.

Immunogenicity

Because Repatha is a biologic, there’s always a theoretical concern that the body could develop antibodies against the drug itself, potentially blunting its effectiveness. In practice, this has been a non-issue with evolocumab. It’s a fully human antibody, meaning its structure closely mirrors proteins the immune system already recognizes as “self.” In the renal impairment study discussed earlier, no patients tested positive for anti-evolocumab antibodies.²¹ Across the broader clinical trial program, anti-drug antibody rates have been very low and have not correlated with loss of effectiveness or safety concerns. This stands in contrast to some other biologic therapies where immunogenicity can be a real clinical problem, and it’s one reason Repatha’s dosing doesn’t typically need to be escalated over time to maintain the same LDL reduction.

Missed Doses and Timing Flexibility

Life happens, and injectable medications occasionally get skipped or delayed. If you miss a dose by fewer than seven days on the every-two-week schedule, the guidance is to take it as soon as you remember and then resume your original schedule. If more than seven days have passed, skip that dose entirely and pick up with the next one on the regular timeline. The same general approach applies to the monthly schedule: take a late dose if you’re still within a reasonable window, but don’t double up.

Because evolocumab’s half-life is relatively long, a short delay of a day or two is unlikely to cause a meaningful rebound in LDL. But prolonged gaps, say skipping an entire monthly dose, will allow PCSK9 levels to recover and LDL to rise back toward untreated levels. The effect isn’t permanent; your next on-time dose will bring levels back down. But consistency matters for sustained cardiovascular protection, especially in people whose risk profiles are the reason they’re on the drug in the first place.